Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
563-01-013 ISMRM Abstract

In Situ Postmortem 7 Tesla MRI of Nigral Iron in Parkinson’s Disease: A Histopathologically Validated Study

Primary: Neuro - Parkinson's Disease
Secondary: Contrast Mechanisms - Susceptibility/QSM
563-01-013 · Novel Neuro Applications · Wednesday, 13 May, 8:20 AM–9:15 AM · Digital Posters Row D
Keywords: Parkinson's Disease Ageing Quantitative Susceptibility Mapping (QSM) Histopathology Post-mortem
Accepted
Rahul Gaurav 1,2,3, Roberta D Rodriguez4, Shreya Shrivastava1,2,3, Vineeth Radhakrishnan1,2,3, Fábio Otsuka4, Khallil T Chaim4, Stéphane Lehéricy1,2,3,5, Maria Garcia Otaduy4
1Mov'IT : Movement Investigation and Therapeutics, Paris Brain Institute - ICM, Inserm U1127, CNRS UMR 7225, Sorbonne Université, UMR S 1127, Paris, France
2Center for Neuroimaging Research (CENIR), Paris Brain Institute, Paris, France
3Sorbonne University, AP-HP, Paris Brain Institute – ICM, Pitié Salpêtrière University Hospital, Paris, France
4LIM44-Instituto de Radiologia, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, Brazil, Brazil
5Department of Neuroradiology, Pitié Salpêtrière Hospital, APHP, Paris, France
Presenting Author: Rahul Gaurav

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Langkammer, C., Schweser, F., Krebs, N., Deistung, A., Goessler, W., Scheurer, E., Sommer, K., Reishofer, G., Yen, K., Fazekas, F., Ropele, S., & Reichenbach, J. R. (2012). Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. NeuroImage, 62(3), 1593–1599. https://doi.org/10.1016/j.neuroimage.2012.05.049 [doi]
2. Liu, C., Wei, H., Gong, N. J., Cronin, M., Dibb, R., & Decker, K. (2015). Quantitative Susceptibility Mapping: Contrast Mechanisms and Clinical Applications. Tomography (Ann Arbor, Mich.), 1(1), 3–17. https://doi.org/10.18383/j.tom.2015.00136 [doi]
3. Gaurav R, Lejeune FX, Santin MD, Valabrègue R, Pérot JB, Pyatigorskaya N, Mangone G, Leu-Semenescu S, Villain N, Habert MO, Vidailhet M, Arnulf I, Corvol JC, Lehéricy S. Early brain iron changes in Parkinson's disease and isolated rapid eye movement sleep behaviour disorder: a four-year longitudinal multimodal quantitative MRI study. Brain Commun. 2025 Jun 2;7(3):fcaf212. doi: 10.1093/braincomms/fcaf212. PMID: 40585816; PMCID: PMC12203178. [doi] [pmid]
4. Biondetti, E., Gaurav, R., Yahia-Cherif, L., Mangone, G., Pyatigorskaya, N., Valabrègue, R., Ewenczyk, C., Hutchison, M., François, C., Arnulf, I., Corvol, J. C., Vidailhet, M., & Lehéricy, S. (2020). Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease. Brain : a journal of neurology, 143(9), 2757–2770. https://doi.org/10.1093/brain/awaa216 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/563-01-013